Thus, it is likely that TM4SF5-expressing hepatocytes in chronic liver diseases including HCC may still utilize extracellular ALB for gain of function during earlier pathological stages with less hepatocyte damage or malignancy. The gene discussed is TM4SF5; the disease is hepatocellular carcinoma.